Clinical trial
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning…
NCT00171145 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171145 |
|---|---|
| Title | A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. |
| Official title | A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Overactive Bladder Syndrome |
| Intervention type | Drug |
| Interventions | Darifenacin, Placebo |
| Enrollment | 445 |
| Start date | Apr 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 23, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: